The Global Organization for EPA and DHA Omega-3s (GOED) has introduced an interactive tool to catalog all human studies on EPA and DHA omega-3s. The Clinical Study Database (CSD) provides a comprehensive searchable database with over 45,000 studies, allowing users to filter by outcome, population demographics, study size or dosage.
A recent study published in the Journal of Clinical Lipidology found that omega-3 levels were better predictors of death risk than serum cholesterol. The study showed a 33% reduction in mortality risk among participants with highest omega-3 blood levels, indicating a potential marker for overall health.
A meta-analysis of 14 randomized controlled trials found that consuming EPA and DHA omega-3s reduced the risk of cardiac death by an average of 8%. Higher risk reduction was seen in individuals with high cholesterol or triglycerides, with a significant 17% reduction in these groups.
A study found that high EPA and DHA omega-3 levels in red blood cells were associated with a lower risk of all-cause mortality in postmenopausal women. Women aged 65-80 with the highest quartile of omega-3 blood levels were 20% less likely to die from any cause.
A new study has found that increasing intake of EPA and DHA omega-3s can help reduce the risk of coronary heart disease, particularly among populations with high triglycerides and LDL cholesterol levels. The study analyzed data from 93,000 and 732,000 subjects across 18 randomized controlled trials and 16 prospective cohort studies.
A recent study published in the Journal of Alzheimer's Disease found that DHA supplementation improved Full-Scale Intelligence Quotient (IQ) by 10% and increased scores on Information and Digit Span sub-tests, indicating significant improvements in long-term and short-term memory.
A recent meta-analysis in Scientific Reports supports the link between omega-3s and reduced mortality. The analysis showed a 9% reduced risk of all-cause death associated with high versus low omega-3 intake.
A new meta-analysis found that omega-3 polyunsaturated fatty acids significantly reduce postoperative cardiac arrhythmias and the length of hospital stay by up to 2.4 days in cardiac surgery patients.
A new meta-analysis supports the link between Omega-3 supplementation and reduced major depressive disorder (MDD) rates. The study found a comparable benefit to antidepressants in patients taking EPA and DHA supplements.
A new study highlights the potential positive impact of consuming EPA and DHA omega-3s derived from menhaden on US public health. The consumption of 1000mg per day may reduce the risk of coronary heart disease and nationwide healthcare costs by $1.7 billion.
A recent paper published in Prostaglandins, Leukotrienes and Essential Fatty Acids identifies experimental design issues in neutral studies questioning the benefits of omega-3s for heart health. The study suggests that these issues may be responsible for the lack of significant effects on cardiovascular disease outcomes.